A Major Functional Difference between the Mouse and Human ARF Tumor Suppressor Proteins*

Suppression of tumorigenesis is considerably more stringent in the human than in the much shorter lived mouse species, and the reasons for this difference are poorly understood. We investigated functional differences in the control of the ARF (alternative reading frame) protein that acts upstream of p53 and is encoded along with p16 INK4a at a major tumor suppressor locus in both the human and mouse genomes. The mouse and human ARF proteins are substantially divergent at their carboxyl termini. We have shown that the mouse ARF protein (p19ARF) interacts with Pex19p in the cell cytoplasm leading to its nuclear exclusion and repression of its p53 activation function. The human ARF protein (p14ARF) is substantially smaller than its mouse counterpart and is not subject to this functional inactivation by Pex19p. In an identical cellular background, ribozymes directed against Pex19p enhanced p19ARF- but not p14ARF-activated p53 function. This is the first demonstration of a functional difference between the mouse and human ARF proteins. In view of the major role of ARF in tumor suppression, this distinction may contribute to the different levels of tumor proneness of these species.

[1]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[2]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[3]  David M. Livingston,et al.  p19ARF targets certain E2F species for degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Toshiaki Tanaka,et al.  p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts , 1999, Oncogene.

[5]  G. Peters,et al.  Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. , 2000, Progress in cell cycle research.

[6]  R. Wanders,et al.  Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Hemminki,et al.  Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. , 1999, Melanoma research.

[8]  M. Lindström,et al.  MdmX Binding to ARF Affects Mdm2 Protein Stability and p53 Transactivation* , 2001, The Journal of Biological Chemistry.

[9]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[10]  C. Larsen,et al.  Human ARF protein interacts with Topoisomerase I and stimulates its activity , 2001, Oncogene.

[11]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[12]  M. Crouzet,et al.  Stable DNA-binding yeast vector allowing high-bait expression for use in the two-hybrid system. , 1997, BioTechniques.

[13]  A. Lloyd.  p53: only ARF the story , 2000, Nature Cell Biology.

[14]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[15]  M. Serrano,et al.  Tumor suppressors and oncogenes in cellular senescence☆ , 2000, Experimental Gerontology.

[16]  A. Okamoto,et al.  Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers , 2000, Oncogene.

[17]  D. Beach,et al.  p16INK4A and p19ARF act in overlapping pathways in cellular immortalization , 2000, Nature Cell Biology.

[18]  J. Benítez,et al.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. , 1998, The American journal of pathology.

[19]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[20]  R. DePinho,et al.  The INK4A/ARF locus and its two gene products. , 1999, Current opinion in genetics & development.

[21]  L. Chin,et al.  The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.

[22]  M. Loda,et al.  Obligate Roles for p16Ink4a and p19Arf-p53 in the Suppression of Murine Pancreatic Neoplasia , 2002, Molecular and Cellular Biology.

[23]  N. Forsyth,et al.  Replicative senescence as a barrier to human cancer. , 2000, Biochemical Society transactions.

[24]  C. Korgaonkar,et al.  ARF Function Does Not Require p53 Stabilization or Mdm2 Relocalization , 2002, Molecular and Cellular Biology.

[25]  T. Parisi,et al.  The Human Tumor Suppressor ARF Interacts with Spinophilin/Neurabin II, a Type 1 Protein-phosphatase-binding Protein* , 2001, The Journal of Biological Chemistry.

[26]  G. Peters,et al.  Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. , 1999, Cancer research.

[27]  R. Reddel,et al.  p16(INK4a) and the control of cellular proliferative life span. , 1999, Carcinogenesis.

[28]  J. Weitzman.  p16Ink4a and p19Arf: terrible twins , 2001 .

[29]  S. Asano,et al.  Factors Governing the Activity In Vivo of Ribozymes Transcribed by RNA Polymerase III , 1999, Journal of Virology.

[30]  M. Castellano,et al.  Genes involved in melanoma: an overview of INK4a and other loci. , 1999, Melanoma research.

[31]  R. Erdmann,et al.  Pex19p, a Farnesylated Protein Essential for Peroxisome Biogenesis , 1998, Molecular and Cellular Biology.

[32]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[33]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[34]  R. Rachubinski,et al.  Yarrowia lipolytica cells mutant for the peroxisomal peroxin Pex19p contain structures resembling wild-type peroxisomes. , 2001, Molecular biology of the cell.

[35]  M. Serrano.  The tumor suppressor protein p16INK4a. , 1997, Experimental cell research.

[36]  F. Zindy,et al.  Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. , 1999, Cancer research.

[37]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[38]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[39]  Charles J. Sherr,et al.  Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.

[40]  D. Quelle,et al.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Taira,et al.  Relationships between the Activities in Vitro and in Vivo of Various Kinds of Ribozyme and Their Intracellular Localization in Mammalian Cells* , 2001, The Journal of Biological Chemistry.

[42]  M. Roussel,et al.  p53-independent functions of the p19(ARF) tumor suppressor. , 2000, Genes & development.

[43]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[44]  R. Reddel,et al.  Pex19p Dampens the p19ARF-p53-p21WAF1 Tumor Suppressor Pathway* , 2001, The Journal of Biological Chemistry.

[45]  G. Peters,et al.  Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus , 2001, Nature Cell Biology.

[46]  E. Brambilla,et al.  Human ARF binds E2F1 and inhibits its transcriptional activity , 2001, Oncogene.

[47]  W. B. Snyder,et al.  Pex19p interacts with Pex3p and Pex10p and is essential for peroxisome biogenesis in Pichia pastoris. , 1999, Molecular biology of the cell.

[48]  M. Murphy,et al.  The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.

[49]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Fujita,et al.  Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  O. Tachibana,et al.  Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. , 2000, Cancer research.

[52]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.

[53]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Wenyi Wei,et al.  Role of p14ARF in Replicative and Induced Senescence of Human Fibroblasts , 2001, Molecular and Cellular Biology.

[55]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.